Full Press Release Details
Jasper Therapeutics Announces Appointment of
Ronald Martell as Chief Executive Officer
Continue as Chairman, Board of Directors ---
REDWOOD CITY, CA; February 28, 2022 - Jasper
Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment
of Ronald Martell as the company's Chief Executive Officer effective March 15, 2022.
"Ron is an experienced CEO with a proven
track record of leading public biopharmaceutical companies in all phases of development, and we are pleased to welcome him as the Jasper
CEO to lead the company through the next stage of growth and success," said Bill Lis, Chairman of Jasper Therapeutics. "Ron
brings to Jasper a depth of experience in oncology and cell therapy development and commercialization, as well as deep relationships across
the industry. His leadership will allow Jasper to maximize the potential of our clinical stage targeted conditioning program, as
well as our research stage novel cellular therapeutics pipeline."
"Jasper's JSP191 and mRNA engineered
stem cell graft programs have the potential to transform multiple diseases by providing safer and more effective stem cell transplant,"
said Mr. Martell. "I am particularly impressed by recent Phase 1b data in MDS/AML showing that JSP191 is well- tolerated with no
treatment-related severe adverse events and achieved 100% successful engraftment with clearance of all diseased cells in 12 of 15 patients.
I believe that JSP191 can become part of standard of care conditioning regimens across allogeneic and gene therapy stem cell transplants.
With a robust pipeline and solid balance sheet in place, I look forward to building on Jasper's momentum and advancing our pipeline
to the next phases of development."
Mr. Martell is a veteran biopharmaceutical executive
and serial entrepreneur, having founded five companies and served on the boards of directors of several others. Prior to joining Jasper,
Mr. Martell served as the President and CEO of MorphImmune, Inc., a private platform company advancing a highly specific targeting technology
that uses a ligand-linked payload to reprogram the immune system. Previously, he was President and CEO of Nuvelution Pharma. He was also
Co- Founder and Executive Chairman of Indapta, Orca Bio and Co-Founder and CEO of Achieve Life Sciences, where he led the merger of the
company with Oncogenex. Mr. Martell has served as the CEO of three public biopharmaceutical companies, including Sevion and NeurogesX,
and has overseen billions of dollars in industry transactions. Earlier in his career, Martell served as Senior Vice President of Commercial
Operations at ImClone Systems, where he was instrumental in deals with Bristol-Myers Squibb and Merck KGaA and built ImClone Systems'
worldwide operations to market and commercialize Erbitux . He also served in various leadership positions with Genentech
where, as Group Manager, Oncology, he was responsible for building the company's oncology franchise, including the launch of Herceptin
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company
focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two
potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that
clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable
safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing
its preclinical mRNA engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and
autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem
cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible
today. For more information, please visit us at jaspertherapeutics.com.
Forward-Looking Statements
Certain statements included in this press
release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United
States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as
"believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect," "should," "would," "plan,"
"predict," "potential," "seem," "seek," "future," "outlook"
and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to, statements regarding the potential of the Company's JSP191 and
mRNA engineered stem cell graft programs. These statements are based on various assumptions, whether or not identified in this press
release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a
guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are
difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of
Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political
and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical
development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding
the regulatory pathway for Jasper's product candidates; the risk that prior study results may not be replicated; the risk that
clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the
risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that
Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to
try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's
business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical
services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and
timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic;
the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational
products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to
time in Jasper's filings with the SEC. If any of these risks materialize or Jasper's assumptions prove incorrect, actual
results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these
forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press
release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
John Mullaly (investors)
Jeet Mahal (investors)